Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05498584 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Targeting LOXL2 and Cardiac Fibrosis for Post-acute Heart Failure Treatment- A Prospective Study

StatusUnknown
PhaseNot specified
Started2022-08-25
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 16, 2024 (before its estimated August 30, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2026-09-06
Trial status changed: Recruiting → Unknown
2024-07-15
Recruiting→Unknown Study Status, Study Design v3
Trial statusRecruiting→Unknown
2022-09-14
Study Status v2
Start dateestimated 2022-08-15→confirmed 2022-08-25
2022-08-16
Study Status, Study Description v1
Start date2022-08-01→2022-08-15
Study description+109 characters
[...] re quality and reduce the readmission rate on July 1, 2017. OurA previous study showed heart failure disease management prog [...] rhosis, lung fibrosis, cardiac fibrosis, and heart failure. OurAn animal study showed the correlation between cardiac fibrosis and LOXl2 serum level. In oura previous clinical prospective cohort study (CMRPG8H1271), wethe investigators recruited 40 patients who were discharged from acute decomp [...] period, 10 patients suffered from cardiovascular mortality. WeThe investigators found that the LOXl2 level is higher in patients with morta [...] uggested that fibrotic changes in the hear [...]
2022-08-10
Original filing
A previous study demonstrated that a multidisciplinary cardiac rehabilitation (CR) program was associated with reduced medium- to long-term all-cause mortality in a retrospective propensity score-matched study. The investigators will further investigate the predictors including LOXl2, cardiac MRI, and endothelial function that will benefit from a successful CR.
Trial Details
NCT Number NCT05498584
Lead Sponsor Chang Gung Memorial Hospital
Conditions Heart Failure; With Decompensation
Enrollment 130 participants
Start Date 2022-08-25
Primary Completion 2025-08-30 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2024-07-16